全球非專利注射劑市場規模、佔有率、趨勢和成長分析報告（2026-2034）

預計非專利注射劑市場將從 2025 年的 1,581.9 億美元成長到 2034 年的 4,691.9 億美元，2026 年至 2034 年的複合年成長率為 12.84%。

隨著全球醫療體系致力於在保證醫療品質的同時降低治療成本，全球非專利用學名藥市場正在迅速擴張。非專利學名藥是品牌藥的一種經濟有效的替代方案，廣泛應用於醫院和診所，用於治療包括感染疾病、癌症和心血管疾病在內的多種疾病。不斷上漲的醫療成本和日益加重的慢性病負擔正在推動對這些藥物的需求。

推動市場成長的主要因素之一是多種品牌注射劑的專利到期，這使得製藥公司能夠推出學名藥藥。此外，注射劑因其起效迅速、患者遵守用藥高而日益受到青睞，這也促進了市場擴張。

未來幾年，由於對價格合理的醫療保健解決方案的需求不斷成長以及藥品生產能力的擴大，預計市場將進一步成長。各國政府和醫療機構都在鼓勵使用學名藥以控制醫療成本。此外，對無菌生產技術的投資增加也將有助於開發新的非專利注射劑產品。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球非專利注射劑市場：依產品類型分類

• 市場分析、洞察與預測
• 高分子量注射藥物
• 低分子量注射藥物

第5章 全球非專利注射劑市場：依應用領域分類

• 市場分析、洞察與預測
• 腫瘤學
• 感染疾病
• 循環系統
• 糖尿病
• 免疫學
• 其他

第6章 全球非專利注射劑市場：依容器類型分類

• 市場分析、洞察與預測
• 管瓶
• 預混合料
• 預填充式注射器
• 安瓿
• 其他

第7章 全球非專利學名藥市場：依給藥途徑分類

• 市場分析、洞察與預測
• 靜脈
• 肌肉內部
• 皮下
• 其他

第8章 全球非專利注射劑市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • AstraZeneca
  • Baxter International Inc
  • Biocon
  • Fresenius SE & Co. KGaA
  • GlaxoSmithKline Plc
  • Hikma Pharmaceuticals Plc
  • Johnson & Johnson Services Inc
  • Lupin Ltd
  • Merck KGaA
  • Mylan NV
  • Novartis AG（Sandoz International GmbH）
  • Pfizer Inc
  • Piramal Pharma Solutions
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd

The Generic Injectables Market size is expected to reach USD 469.19 Billion in 2034 from USD 158.19 Billion (2025) growing at a CAGR of 12.84% during 2026-2034.

The Global Generic Injectables Market is expanding rapidly as healthcare systems worldwide focus on reducing treatment costs while maintaining high-quality care. Generic injectable drugs offer cost-effective alternatives to branded medications and are widely used in hospitals and clinics for treating various conditions such as infections, cancer, and cardiovascular diseases. Increasing healthcare expenditure and the rising burden of chronic diseases are driving demand for these medications.

One of the key factors supporting market growth is the expiration of patents for several branded injectable drugs, allowing pharmaceutical companies to introduce affordable generic versions. Additionally, the growing preference for injectable formulations due to their rapid therapeutic effect and improved patient compliance is contributing to the expansion of the market.

In the coming years, the market is expected to grow further due to rising demand for affordable healthcare solutions and expanding pharmaceutical manufacturing capabilities. Governments and healthcare organizations are encouraging the use of generic medicines to control healthcare costs. Furthermore, increasing investments in sterile manufacturing technologies will support the development of new generic injectable products.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product Type

• Large Molecule Injectables
• Small Molecule Injectables

By Application

• Oncology
• Infectious Diseases
• Cardiology
• Diabetes
• Immunology
• Others

By Container Type

• Vials
• Premix
• Prefilled Syringes
• Ampoules
• Others

By Route of Administration

• Intravenous
• Intramuscular
• Subcutaneous
• Others

COMPANIES PROFILED

• AstraZeneca, Baxter International Inc, Biocon, Fresenius SE amp Co KGaA, GlaxoSmithKline plc, Hikma Pharmaceuticals plc, Johnson amp Johnson Services Inc, Lupin Ltd, Merck KGaA, Mylan NV, Novartis AG Sandoz International GmbH, Pfizer Inc, Piramal Pharma Solutions, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL GENERIC INJECTABLES MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product Type
• 4.2. Large Molecule Injectables Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Small Molecule Injectables Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL GENERIC INJECTABLES MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Cardiology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Diabetes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Immunology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL GENERIC INJECTABLES MARKET: BY CONTAINER TYPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Container Type
• 6.2. Vials Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Premix Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Prefilled Syringes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Ampoules Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL GENERIC INJECTABLES MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Route Of Administration
• 7.2. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Intramuscular Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Subcutaneous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL GENERIC INJECTABLES MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Product Type
  • 8.2.2 By Application
  • 8.2.3 By Container Type
  • 8.2.4 By Route Of Administration
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Product Type
  • 8.3.2 By Application
  • 8.3.3 By Container Type
  • 8.3.4 By Route Of Administration
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Product Type
  • 8.4.2 By Application
  • 8.4.3 By Container Type
  • 8.4.4 By Route Of Administration
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Product Type
  • 8.5.2 By Application
  • 8.5.3 By Container Type
  • 8.5.4 By Route Of Administration
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Product Type
  • 8.6.2 By Application
  • 8.6.3 By Container Type
  • 8.6.4 By Route Of Administration
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL GENERIC INJECTABLES INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 AstraZeneca
  • 10.2.2 Baxter International Inc
  • 10.2.3 Biocon
  • 10.2.4 Fresenius SE & Co. KGaA
  • 10.2.5 GlaxoSmithKline Plc
  • 10.2.6 Hikma Pharmaceuticals Plc
  • 10.2.7 Johnson & Johnson Services Inc
  • 10.2.8 Lupin Ltd
  • 10.2.9 Merck KGaA
  • 10.2.10 Mylan N.V
  • 10.2.11 Novartis AG (Sandoz International GmbH)
  • 10.2.12 Pfizer Inc
  • 10.2.13 Piramal Pharma Solutions
  • 10.2.14 Sun Pharmaceutical Industries Ltd
  • 10.2.15 Teva Pharmaceutical Industries Ltd